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Abstract
The design of sensors to monitor the activity state of specific protein kinases is challenging due to
the complexity of eukaryotic kinomes. Here we describe a peptide-based photaffinity probe that
specifically labels the active conformation of the Abl tyrosine kinase.
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Protein kinases are key players in intracellular signaling pathways that control all aspects of
cell behavior. Because protein kinases often promote cell survival and growth, aberrant
kinase activity frequently contributes to cancer, and kinase inhibitors have become
important anti-cancer drugs.[1] Accordingly, much effort has been expended towards the
design of protein or peptide-based reporters to probe the activity of specific protein kinases
in complex systems (cell lysates, intact cells, tissues or tumors).[2] However, these
approaches require that the substrate must be exquisitely specific for the kinase of interest, a
major challenge given that there are over 500 human protein kinases that could potentially
provide “off-target” activity.[3] An alternative to the use of substrates to profile enzyme
activity in crude systems is to use affinity probes that bind to the enzyme in an activity-
dependent manner. Because such activity-based probes (ABPs) covalently label their targets,
binding to multiple enzymes is actually advantageous, as it can facilitate profiling of entire
classes of molecules. ABPs have been developed and applied most extensively for
hydrolytic enzymes, including lipid esterases, proteases, and phosphatases,[4] but have been
lacking for protein kinases. We describe here a photoaffinity probe based on a consensus
peptide substrate that specifically labels the active conformation of the oncogenic protein
tyrosine kinase Abl. In some contexts this probe behaves like an ABP, reporting on the
activation state of the kinase. Our approach should allow for the general design of
conformation-specific probes for many protein kinases.
A nearly universal feature of kinase activation involves conformational reorganization of a
region adjacent to the catalytic cleft called the activation loop.[5] The activation loop
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constitutes a portion of the protein substrate binding site, suggesting that probes based on a
peptide substrate are likely to be specific for the active conformation. To test this
hypothesis, we generated a probe targeting the non-receptor tyrosine kinase Abl (Scheme 1),
an established oncology target deregulated in chronic myelogenous leukemia through a gene
rearrangement leading to a constitutively active fusion protein (BCR-Abl). We based our
probe on a consensus substrate (ABLtide, Figure 1) generated through peptide library
screening.[6] ABPs typically consist of a reactive group that targets the enzyme linked to a
reporter, either a fluorescent tag or affinity handle.[7] To allow covalent targeting of the
kinase, we incorporated a photocrosslinking phenyl azide group (4-azidophenylalaine, Z)
into the peptide sequence. We chose to insert the Z residue at the P+2 position (two residues
downstream of the phosphorylation site), as X-ray crystal structures of Abl-peptide
complexes[8] suggested that substitution at that position would not affect peptide binding. To
facilitate detection, we incorporated a biotin moiety at the C-terminus to generate the probe
(ABL-Z, Figure 1).
Incubation of purified recombinant Abl with ABL-Z followed by UV irradiation resulted in
covalent incorporation of biotin into the kinase as judged by detection with streptavidin-
horseradish peroxidase (HRP) following SDS-PAGE and transfer to a membrane (Figure 1).
Labeling was UV-dependent, and could be competed with increasing concentrations of
unlabeled peptide but not a scrambled peptide control. When labeling was carried out in the
presence of equal amounts of another tyrosine kinase, Src, label was incorporated
predominantly into Abl and to a lesser degree into the off-target kinase. These results
suggest that ABL-Z crosslinks to Abl specifically through binding to the active site cleft.
UV-dependent labeling of Abl also occurred in a crude cell lysate (Figure S1). In this
context detection of label incorporation was accomplished by immunoblotting for the
presence of Abl among proteins isolated using avidin resin. Biotin affinity isolation was
necessary due to a high degree of labeling of other proteins, presumably due to excess label
in free solution reacting through random collision. However, in crude lysates we could
detect Abl with high sensitivity (<24 fmol kinase).
To establish whether ABL-Z could be used in a manner similar to an ABP, we first
performed experiments with recombinant Abl in which we manipulated its activation state.
Abl purified from mammalian cells exhibited a basal level of activity as detected by
ABLtide phosphorylation (Figure 2). Abl activity is enhanced by phosphorylation at
multiple sites within the kinase,[9] and lambda phosphatase (λPP) treatment reduces its
activity. We also generated a triple point mutant (G2A/P242E/P249E, or GPP) that disrupts
intramolecular interactions that restrain Abl kinase activity,[10] resulting in constitutively
higher activity than wild-type (WT) Abl. These three forms of Abl were subjected to
labeling with ABL-Z. The extent of labeling increased with increasing catalytic activity,
indicating that in this context ABL-Z behaves as expected for an ABP (Figure 2).
As another means to assess the specificity of our probe for the active form of Abl, we used
two clinical inhibitors known to bind specific conformations of the kinase. STI-571
(imatinib/Gleevec) induces an inactive conformation of Abl in which the active site cleft is
occluded through an intramolecular pseudosubstrate interaction.[11] In contrast, the dual Src/
Abl inhibitor dasatinib binds to the active conformation of Abl.[12] In these experiments WT
or mutant Abl was expressed in mammalian cells and labeling was performed in crude cell
lysates. As anticipated, STI-571 almost completely blocked labeling by ABL-Z, while
dasatinib actually increased the extent of labeling (Figure 3). We confirmed that both
compound inhibited Abl when purified from the same cell lysates (Figure S2). These results
provide further evidence that ABL-Z specifically targets the active conformation of Abl.
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These results illustrate the use of peptide substrate-based probes to assess the activity state
of protein kinases in crude systems. Protein kinase affinity labels have previously been
generated by derivatizing ATP or ATP-competitive small molecule inhibitors.[13] In
addition, affinity resins consisting of immobilized inhibitors have been used to profile kinase
expression in cell lysates.[14] These approaches have been valuable for profiling kinase
expression and for assessing inhibitor selectivity and potency in situ. However, because
ATP or inhibitor affinity need not correlate with the activity state of a kinase, these probes
are not necessarily suitable for activity-based profiling. In contrast, because kinase
activation can involve rearrangement of the peptide binding site, peptide substrate-based
probes should frequently bind in an activity-dependent manner.
While the current probe was designed to target Abl, alterations in the peptide sequence
should enable tuning the reactivity of such probes to target essentially any kinase of interest.
It is unlikely that a short peptide sequence will be absolutely specific for a single kinase.
However, cross-reactivity with other kinases does not limit use of such probes, since specific
targets of interest can be detected by immunoblotting or by mass spectrometry following
affinity isolation of bound proteins. In this way a limited number of probes can potentially
be used to detect activity of a large number of kinases. While detection of endogenous
kinase using the current probe is hampered by low affinity for Abl leading to low
crosslinking efficiency (<1.3%), increasing peptide affinity through screening of peptide
libraries[15] or the use of bivalent inhibitors[16] should allow detection of endogenous
kinases in an activity-dependent manner. In addition, appending cell penetrating peptide
sequences would allow their use in intact cells. In this way peptide substrate based probes
should allow one to establish the repertoire of active kinases present in a cell line or tumor,
and may thereby suggest new therapeutic targets.
Experimental Section
Experimental details are provided in the Supporting Information.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Peptide-based photoaffinity probe for Abl kinase. A, Probe and consensus peptide sequence.
B, Labeling of purified Abl with 5 μM ABL-Z in the presence of indicated peptides (μM
concentrations are shown). C, ABL-Z preferentially labels Abl in the presence of equimolar
Src kinase. Left lane, biotin signal detected using streptavidin-HRP; right lane, Coomassie
Blue stain showing total protein.
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ABL-Z probe accessibility correlates with Abl kinase activity. Left panel, peptide kinase
activity of either WT or constitutively active mutant (GPP) Abl is shown subsequent to
mock treatment or dephosphorylation with λPP. Right panel, photoaffinity labeling of the
same forms of Abl with ABL-Z.
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Labeling of Abl in the presence of inhibitors that bind to distinct conformations of the
kinase. Crude lysates of HEK293T cells expressing WT or mutant Abl were treated with 5
μM ABL-Z in the presence of the indicated concentrations of inhibitor prior to irradiation
and analysis of probe crosslinking.
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Labeling and detection of the Abl tyrosine kinase. The active conformation of Abl with an
intact peptide substrate binding site can be induced either by phosphorylation of the kinase
or by binding of specific inhibitors such as dasatinib. Conversely, dephosphorylation of Abl
or binding of the inhibitor STI571 induces an inactive conformation that is incapable of
binding peptide substrates. A biotin-conjugated peptide photoaffinity label binds to the
substrate-binding cleft of Abl in its active conformation. Irradiation of the complex triggers
photocrosslinking, and the extent of probe incorporation correlates with the activity state of
the kinase.
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